Study #2020-0608
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments
MD Anderson Study Status
Enrolling
Treatment Agent
PDR001
Description
The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumors
Study phase:
Phase I
Physician name:
Funda Meric-Bernstam
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-479-2433
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.